Cyclotides are plant proteins with exceptional stability owing to the presence of a cyclic backbone and three disulfide bonds arranged in a cystine knot motif. Accordingly, they have been proposed as templates to stabilize bioactive epitopes in drug-design applications. The two main subfamilies, referred to as the Mö bius and bracelet cyclotides, require dramatically different in vitro folding conditions to achieve the native fold. To determine the underlying elements that influence cyclotide folding, we examined the in vitro folding of a suite of hybrid cyclotides based on combination of the Mö bius cyclotide kalata B1 and the bracelet cyclotide cycloviolacin O1. The folding pathways of the two cyclotide subfamilies were found to be different and influenced by specific residues within intercysteine loops 2 and 6. Two changes in these loops, a substitution in loop 2 and an addition in loop 6, enabled the folding of a cycloviolacin O1 analogue under conditions in which folding does not occur in vitro for the native peptide. A key intermediate contains a native-like hairpin structure that appears to be a nucleation locus early in the folding process. Overall, these mechanistic findings on the folding of cyclotides are potentially valuable for the design of new drug leads. Antioxid. Redox Signal. 11, 971-980.
Introduction
T he cyclotides (12) are the largest family of circular proteins currently known and contain a unique structural motif referred to as the cyclic cystine knot (CCK). This extremely stable motif is formed by the combination of a cyclic backbone and three conserved disulfide bonds arranged in a knotted topology. Several backbone loops project from the stable molecular core of cyclotides, as illustrated in Fig. 1 . The primary function of cyclotides is thought to be as plant defense agents based on their potent insecticidal activity against the larvae of several Helicoverpa species (4, 25, 31, 32) . However, cyclotides are functionally versatile and display a range of other bioactivities, including uterotonic (22) (23) (24) , anti-HIV (27, 28) , cytotoxic (35, 44) , hemolytic (17, 30, 42, 46) , antimicrobial (46) , antifouling (21) , nematicidal (10) , and molluscicidal (38) activities. More than 100 cyclotides have been characterized (36, 47) , with hypervariable sequences occupying the backbone loops. The combined features of exceptional stability, functional diversity, and an ability to tolerate a wide range of sequences make cyclotides potentially useful as molecular engineering templates onto which bioactive epitopes can be grafted and thereby stabilized (11, 14) . Other peptides, such as knottins (8) and BPTI (39) , have been used as scaffolds to graft nonnative activities, highlighting the potential of peptide scaffolds in drug design.
Two main cyclotide subfamilies have been defined: the Mö bius and bracelet subfamilies, based on the geometry of an X-Pro peptide bond in the circular backbone (12) . In Mö bius cyclotides a cis-peptide bond in loop 5 results in a conceptual 180-degree twist in the backbone, as illustrated in Fig. 1 . In contrast, bracelet cyclotides lack the corresponding proline residue and have a bracelet (all-trans) topology. Loops 1 and 4 of cyclotides form part of the cystine knot and are highly conserved across the two subfamilies. Despite some degree of sequence similarity within subfamilies, loops 2, 3, 5, and 6 vary in size and sequence across different cyclotides, as shown in Fig. 1 . Based on the presence of a CCK topology (20) , the two peptides Momordica cochinchinensis trypsin inhibitor I (MCoTI-I) and MCoTI-II, discovered in 2000 (29) , constitute a third cyclotide subfamily known as the trypsin-inhibitor cyclotides (13) . These peptides are also referred to as ''cyclic knottins,'' as they show high sequence similarity to linear trypsin inhibitors found within certain squash plants (7) .
Mö bius cyclotides can be efficiently synthesized by first assembling linear precursor sequences via solid-phase synthesis and then using a thioester-mediated strategy to generate the cyclic product (17, 46) . Under alkaline folding conditions, cyclization and oxidation of the cysteines occur in a single step to give the natively folded conformation in high yields. Unlike conventional proteins that generally have hydrophobic residues in the protein core, native cyclotides have many of their hydrophobic residues exposed on the molecular surface. Inclusion of the hydrophobic agent isopropanol in the folding medium significantly increases the folding efficiency of the prototypical Mö bius cyclotide kalata B1, presumably by stabilizing the patch of hydrophobic residues that is exposed to solvent on folding (17) .
Despite the high yields obtained for folding of Mö bius cyclotides, the folding of bracelet cyclotides has been problematic. In early studies of cyclotide synthesis, Tam et al. (45) reported that synthetic bracelet cyclotides require complex folding conditions and selective cysteine protection followed by directed oxidative folding to attain the native conformation. Recently, successful in vitro folding conditions for the bracelet cyclotide cycloviolacin O2 were reported that enabled folding yields up to *50% (34) . The optimal folding conditions were established after many attempts at folding under a wide range of conditions, including different buffer systems, temperatures, and metal ions, were unfruitful (1), indicating that folding of bracelet cyclotides is not as robust as that of Mö bius cyclotides.
Grafting of bioactive sequences into cyclotide frameworks to derive biologically stable analogues has been proposed as a potential therapeutic application of cyclotides (11, 14) . However, such applications have so far not been extended to members of the bracelet subfamily owing to the difficulties associated with their folding. More than 60% of the cyclotides discovered to date are bracelet cyclotides (43) , and several NMR studies have confirmed that bracelet scaffolds possess naturally stable conformations (5, 32, 33, 37, 40) , indicating that overall, the bracelet subfamily contains a large number of potential scaffolds available for protein-engineering applications. To optimize the range of cyclotide scaffolds used in drug-design applications, an understanding of the fundamental elements that dictate the in vitro folding of bracelet cyclotides is essential.
We examine the key structural features that influence the in vitro folding of the two main cyclotide subfamilies. To determine which backbone loops or key residues in cyclotides influence in vitro folding, we designed a suite of Mö biusbracelet hybrid cyclotides based on the prototypical Mö bius and bracelet cyclotides kalata B1 and cycloviolacin O1, respectively. Our study indicates the structural elements that hinder the folding of bracelet cyclotides under conditions that are effective for Mö bius counterparts and provides a new approach to folding of bracelet cyclotides by introducing simple modifications to the sequence.
Materials and Methods

Synthesis of Möbius-bracelet hybrids and native cycloviolacin O1
A series of bracelet-Mö bius hybrids (hybrids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] and native cycloviolacin O1 were assembled using Boc (t-butoxycarbonyl) chemistry (41) and purified by using methods previously described (9) . In brief, peptides were assembled on a PAM (phenylacetamidomethyl) resin (Applied Biosystems, Foster City, CA) on a 0.3-mmol scale and were designed to contain a C-terminal thioester linker and an Nterminal cysteine (18) . RP-HPLC was used to purify the peptides, and the fractions containing the correct mass detected by ESI-MS were freeze dried and used for the oxidative folding study.
Oxidative folding of hybrids. The hybrid peptides (0.1 mg=ml) were oxidized by using an array of nine smallscale in vitro folding oxidation buffers containing different proportions of 0.1 M ammonium bicarbonate (pH 8.5), isopropanol, and glutathione as shown in Table 1 . The oxidative folding condition that gave a prominent peak in high yield for each peptide was repeated in large scale (total volume of 100 ml) for 24 h, and the folded peptide was purified on a semipreparative column by using a linear gradient of solvent A (0.1% aqueous trifluoroacetic acid) and B (0.05% trifluoroacetic acid in 90% acetonitrile=10% water). Fractions 
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containing the correct mass were identified by ESI-MS and further analyzed with RP-HPLC for purity. Pure fractions (>95% purity) were freeze dried and examined with 1 H-NMR.
NMR experiments. Samples for 1 H-NMR measurements contained *1 mM peptide in 90% water=10% 2 H 2 O (vol=vol) at approximately pH 3. Spectra were recorded at 290 K on a Bruker ARX-600 spectrometer equipped with a shielded gradient unit. Additional spectra were acquired at 310 K for hybrid 8, hybrid 11, and hybrid 15. Two-dimensional NMR spectra were recorded as previously described (16) . Chemical shifts were referenced to internal 2,2-dimethyl-2-silapentane-5-sulfonate.
Oxidative folding of cycloviolacin O1. Oxidative folding was carried out on the linear cycloviolacin O1 assembled with a thioester group and also on the base-treated linear chain from which the thioester group was removed. The thioester group was removed by incubating linear cycloviolacin O1 in 0.1 M potassium hydroxide (pH 11.5) for 10 min followed by purification on an RP-HPLC column.
Oxidative folding and reductive unfolding of hybrid 15. Purified hybrid 15 containing the thioester linker (0.5 mg=ml) was cyclized, and the cysteine residues were maintained in a reduced state by incubation in 0.1 M ammonium bicarbonate buffer (pH 8.5) containing sixfold excess Tris (carboxyethyl) phosphine hydrochloride for 45 min at 258C. For oxidative folding, the purified reduced cyclic hybrid 15 was oxidized in oxidation condition 6. Aliquots were taken out at various time intervals, quenched with 0.4% TFA, and analyzed with analytic RP-HPLC. The major intermediate of hybrid 15 was captured by quenching with 0.4% TFA after 5 min of oxidative folding. The native hybrid 15 was obtained by quenching with 0.4% TFA after 24 h of oxidative folding. The intermediate and the native hybrid 15 were purified on RP-HPLC and characterized with ESI-MS and NMR. For reductive unfolding, purified native hybrid 15 (0.5 mg=ml) was reduced in ammonium bicarbonate buffer (pH 8.5) containing 25 mM dithiothreitol at 258C. Aliquots were taken out at various time intervals, quenched with 0.4% TFA, and analyzed with analytic RP-HPLC.
Oxidative folding and reductive unfolding of kalata B8. Native kalata B8 was isolated from the aerial parts of Oldenlandia affinis plants by using a standard extraction procedure (16) . The peptide (0.5 mg=ml) was reduced in 300 mM DTT containing ammonium bicarbonate buffer (pH 8.5) for 24 h at 258C, purified on HPLC, and used for the oxidative folding study. Oxidative folding was carried out in standard oxidation condition 9, shown in Table 1 . For reductive unfolding, a purified native species (0.1 mg=ml) was dissolved in 0.1 M ammonium bicarbonate (pH 8.0) containing 50 mM DTT at 258C. Aliquots were removed at various time intervals, quenched with 0.4% TFA, and analyzed with analytic RP-HPLC.
Results
The main aim of the current study was to understand the reasons for poor folding of bracelet cyclotides under conditions in which Mö bius cyclotides fold readily. To this end, we used a range of bracelet:Mö bius hybrids to unravel the factors that influence the in vitro folding of cyclotides.
Cycloviolacin O1 is structurally well characterized and was chosen as the prototypical bracelet cyclotide for the investigation. We analyzed the oxidative folding of this cyclotide under a panel of standard oxidation conditions given in Table 1 . Typically, native cyclotides elute late on RP-HPLC as a result of their surface-exposed patch of hydrophobic residues (17) . The native form can readily be confirmed by In an initial series of experiments on the folding of cycloviolacin O1, only misfolded isomers were observed under the panel of conditions tested. To determine whether the folding could be improved if oxidation occurs before cyclization, we also examined the folding of the linear chain. However, the peptide still misfolded, indicating that even when disulfide bond formation occurred before the constraints imposed by cyclization, it was not possible to obtain correctly folded product (data not shown).
We then focussed on kalata B8, a natural hybrid between Mö bius and bracelet subfamilies, to identify the ''offender'' loops responsible for the misfolding of bracelet cyclotides in vitro. In kalata B8, loops 2 and 3 closely resemble Mö bius sequences, and loop 5 resembles bracelet cyclotides (16) , as shown in Fig. 2 . We found that kalata B8 readily folds into a native conformation in vitro, as shown in Fig. 2 , which led to the proposal that loops 2 and 3 are likely to be the reason for the misfolding in bracelet cyclotides. A comparison of bracelet and Mö bius sequences indicates that the amino acid sequences in loops 2 and 3 differ most significantly between the two subfamilies, supporting the proposal that bracelet loops 2 and 3 may have a major impact on folding. Thus, it was proposed that correct folding in cycloviolacin O1 may occur if loops 2 and 3 are substituted with the counterpart Mö bius sequences.
We therefore designed a suite of hybrid peptides containing different loop combinations from both subfamilies, as shown in Fig. 3 , with initial focus on loops 2 and 3. The Mö bius cyclotide kalata B1 and bracelet cyclotide cycloviolacin O1 were used as the representative members for each cyclotide subfamily, as detailed structural data are available for both peptides (40) . Hybrid 1 involves replacement of loop 2 of the cycloviolacin O1 sequence with the kalata B1 loop 2 Fig. 3 , this peptide misfolded in vitro, indicating that engineering a Mö bius loop 2 into a bracelet cyclotide is not sufficient to facilitate folding. Hybrid 2 is a cycloviolacin O1 sequence with loop 3 replaced by the kalata B1 loop 3 sequence. Loop 3 of the bracelet cyclotides is strikingly different in size and sequence from that in Mö bius cyclotides. Unlike in the members of the Mö bius subfamily, loop 3 is helical in the bracelet subfamily and contains residues that form part of the hydrophobic surface of cyclotides (40) . Thus, this region stands out as the most likely region to differentiate the folding pathways of the two subfamilies. Surprisingly, hybrid 2 also misfolded, indicating that the Mö bius loop 3 is not sufficient to induce correct folding. The results from the initial hybrid peptides led us to consider the possibility that the residues that influence folding are embedded in several loops across the sequence and not just confined to a single loop. Thus, we designed hybrid 3, which contains both loops 2 and 3 of cycloviolacin O1, replaced with the corresponding kalata B1 sequences. However, misfolding of this peptide demonstrated that this loop combination does not facilitate correct folding of cycloviolacin O1. Accordingly, we designed several peptides containing other loop combinations. Hybrid 4, containing kalata B1 loops 2 and 5, as well as hybrid 5, which contains kalata B1 loops 3 and 5, both misfolded. Hybrid 6, which contains loops 2, 3, and 5 of kalata B1, also misfolded, indicating that these three loops alone are not sufficient to facilitate folding. However, when loop 6 was also changed into a Mö bius sequence (Hybrid 7), the peptide correctly folded (oxidation condition 8), indicating that loop 6 has a major impact on folding. A sharp late-eluting peak characteristic of a well-folded peptide was observed on RP-HPLC, as shown in Fig. 3 , and was confirmed to contain correctly folded peptide by 1 H-NMR. Specifically, aH chemical shifts are extremely sensitive to structural changes and indicated similarity of this hybrid to native kalata B1 (Fig. 4) .
We chose not to modify loops 1 and 4 for any hybrids, as these loops form part of the cystine knot and are tightly conserved across the two cyclotide subfamilies. Thus, they 
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were not expected to induce differential folding behavior. This assumption is supported by the fact that hybrid 7 contains bracelet loops 1 and 4, but still folds correctly, unlike most bracelet cyclotides. Hybrid 8, which contains kalata B1 loops 3 and 6, misfolded, but hybrid 9, which contains kalata B1 loops 2 and 6, gave a prominent late-eluting peak on RP-HPLC (oxidation condition 6) that was confirmed by NMR to contain the correctly folded material. As shown in Fig. 4 , the aH chemical shifts of hybrid 9 closely follow those of native kalata B1, indicating that it maintains a native cyclotide conformation.
Overall, it became clear that the presence of certain residues in Mö bius loops 2 and 6 synergistically induces correct folding. Further, as hybrid 9 contains bracelet loops 3 and 5, these loops apparently do not cause cyclotides to misfold. These findings for hybrid 9 are quite significant, as they eliminate some of the key misconceptions on bracelet folding (i.e., the misfolding in bracelet cyclotides may be caused by either the helical bracelet loop 3 or the lack of a cis-Pro in the bracelet loop 5). The ability to translocate a bracelet loop 3 onto a Mö bius scaffold without causing it to misfold suggests that loop 3 is a highly permissive region for modification or bioactive epitope insertion. Supporting inferences were made from hybrid 10, designed by replacing loops 2, 3, and 6 of cycloviolacin O1 with the corresponding kalata B1 sequences. This peptide folded into a native-like conformation (oxidation condition 8), indicating that the presence of bracelet loop 5 does not lead to misfolding. This is consistent with a previous study on kalata B1 analogues that had cationic residues from a bracelet counterpart substituted into loop 5 and correctly folded cyclotide analogues were obtained (9) . The next step was to investigate whether specific residues in loops 2 and 6 influence folding. Loop 2 of kalata B1 contains the sequence VGGT, whereas the corresponding loop in cycloviolacin O1 is VYIP. Hybrid 11, designed to contain the VYGT sequence in loop 2, folded into a native conformation (oxidation condition 1), confirming that the Tyr residue that resides in loop 2 of cycloviolacin O1 is not responsible for misfolding. However, the NMR peaks for the Tyr residue were broadened at 290 K, as were the amide protons of Cys 5 , Val 6 , Try 7 , and Asn 11 . Additional spectra acquired at higher temperatures (310 K) allowed the observation of all spin systems, but the broadening behavior indicated that the loop 2 with the VYGT sequence is likely to be flexible. Interestingly, when the sequence in loop 2 was altered to VYIT (hybrid 12), the peptide misfolded, indicating that the Ile residue at the third position of this loop is not compatible with folding into the native conformation.
Next we aimed to identify the specific residues in loop 6 that cause misfolding. Comparison of loop 6 sequences across kalata B1 and cycloviolacin O1 revealed that the sequences are quite similar except for the Thr at the start and Val at the end that are missing in cycloviolacin O1. Thus, we wanted to determine whether these missing residues have an impact on folding in the bracelet framework. Hybrid 13 was designed by modifying the hybrid 6 sequence with an extra Thr at the start of loop 6. This small change resulted in a folded peptide (oxidation condition 8), indicating that introducing a Thr residue can facilitate folding. Hybrid 14 designed by introducing a Val at the end of loop 6 of hybrid 6, however, did not fold correctly, indicating that the Val may not have an influence on folding.
To confirm our findings, we made hybrid 15, which is basically the cycloviolacin O1 sequence with the replacement of the Ile with Gly in loop 2 and the addition of a Thr at the start of loop 6. Hybrid 15 readily folded into a native 
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conformation by using oxidation condition 6, as shown in Fig. 5 , and the presence of the cystine knot topology was confirmed from aH chemical shifts (Fig. 4) . Thus, overall the data show that loops 2 and 6 in native cycloviolacin O1 are the primary cause of misfolding in bracelet cyclotides, and by two changes to the sequence, an amino acid substitution and an amino acid addition, the natively folded conformation can be rescued.
We also examined the reductive unfolding and oxidative folding pathways of hybrid 15. In the reductive unfolding of hybrid 15, no folding intermediates were seen, as shown in Fig. 5 . The peptide was reduced within 10 min in the reduction buffer and resulted in a broad peak on RP-HPLC. The reduced peak for hybrid 15 is significantly broader than that observed for the reduced form of kalata B8, and such broadening on RP-HPLC can indicate the presence of multiple conformations. 
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During oxidative folding of hybrid 15, a major intermediate (MI) was present together with other minor intermediates, as shown in Fig. 5 . MI accumulated as the major species during the initial 6 h of folding, and mass analysis indicated that it is a three-disulfide isomer of hybrid 15. Over a 24-h time period, MI converted to the native form. To gain information on the structure and the disulfide connectivity of MI, we compared the NMR secondary aH chemical shifts of MI, native hybrid 15, and the major intermediate present in the folding pathway of cycloviolacin O2 (1) . Secondary shifts reflect the difference in shift of a given residue in a peptide of interest from that of the same residue in a random coil peptide, and in general, the larger the secondary shifts, the more structured the peptide. As is apparent from Fig. 6 , the secondary shifts for MI residues in loops 1 to 4 are generally smaller than in the native hybrid 15, suggesting a less-well-defined structure in this region. Indeed, the average secondary shift in this region is <0.2 ppm, which makes the region close to random coil. However, the secondary shifts for loop 5 and 6 residues are very similar to those of the native species, indicating a similar conformation in these loops. Loops 5 and 6 of the prototypical bracelet cyclotide cycloviolacin O1 form a b-hairpin, which is a key element of its secondary structure (40) . Specifically, the b-hairpin is formed by strand 1 (residues 19 to 21) and strand 2 (residues 24 to 26), which are linked by a type I b-turn involving residues 21 to 24 (40) . The similarity in the secondary shifts of MI and the native conformation of hybrid 15 in loops 5 and 6 suggests that the b-hairpin motif is most likely intact in MI. The two most significant differences in shifts between hybrid 15 and MI are for the Cys residues preceding loops 5 and 6. Given the similarity of all of the other shifts and hence the similar hairpin conformation, the most likely explanation for the differences in Cys secondary shifts is that they have a different (i.e., nonnative) disulfide connectivity in the intermediate compared with the native hybrid 15 structure.
A characteristic three-disulfide isomer with nonnative disulfide bonds is present in the folding pathway of the bracelet cyclotide cycloviolacin O2 (1). As shown in Fig. 6, a (1) , and the same nonnative connectivity is likely to be present in MI. Thus, overall, our data suggest that the folding intermediate MI identified in the current study, which is formed early in the folding pathway, has a native-like hairpin structure but has nonnative disulfide bonds and is relatively unstructured in the non-hairpin regions. It appears that the b-hairpin structure is a crucial nucleation locus for protein folding in bracelet cyclotides.
Discussion
In this study, we examined the in vitro folding of a series of Mö bius:bracelet hybrid cyclotides and determined that two specific loops play a significant role in the folding. Although the Mö bius subfamily of cyclotides has previously been shown to fold efficiently into the native conformation in vitro, the bracelet cyclotides had until recently proven intractable under a range of standard oxidation conditions. The hybrid cyclotides made for this study were assembled by using solidphase peptide synthesis with a thioester strategy for forming the cyclic backbone. The folding was examined with RP-HPLC and NMR spectroscopy. Characteristic features observed when the cyclotides folded into their native conformations included late-eluting peaks on HPLC and well-dispersed amide signals in NMR spectra. Analysis of the folding yields of the hybrids indicated that the complexity in the in vitro folding of the bracelet cyclotide cycloviolacin O1 is sequence dependent and is hindered mainly by residues in backbone loops 2 and 6. By substituting a single residue in loop 2, and with the addition of an extra residue in loop 6 to resemble the prototypical Mö bius cyclotide kalata B1, it was possible to obtain the native fold for several cyclotide hybrids by using simple in vitro folding conditions. The findings from this work are significant because understanding the mechanistic details of the in vitro folding in cyclotides is potentially invaluable for protein-engineering applications that use cyclotide scaffolds for the stabilization of bioactive sequences.
We determined that replacement of either loop 2 or loop 6 of cycloviolacin O1 with corresponding kalata sequences, one at a time, does not result in a natively folded conformation. Thus, the contribution of these loops individually to the stability of the native fold is not sufficient to induce correct folding. Correct folding in the hybrids is not promoted unless both loops 2 and 6 are replaced simultaneously with Mö biuslike sequences, suggesting the possibility of a synergistic interaction between residues in these loops at some point on the folding pathway or in the final product. The specific residues favorable for folding in the hybrid are a Gly in loop 2 and a Thr in loop 6. The structure in Fig. 6 shows that these residues are remotely located from each other (40) , thus excluding their synergistic interaction in the final fold.
Given the lack of a possible synergistic interaction in the final fold, the observed folding data were then examined for fit to other folding models that would implicate these residues, the first being that they play a cumulative role in stabilizing the final structure, thus driving folding on a thermodynamic basis; and the second, that they have synergistic interactions early in the folding process when they might be closer to one another before the final fold takes shape. Structural analysis of kalata B1 shows that Gly 8 in loop 2 has a positive j angle and is involved in a type I b-turn (40) . In native cycloviolacin O1, the Ile 8 that occupies this position has a negative j angle, even though it is also involved in a type I b-turn. The differences in j angles suggest that differences exist in the orientation of these residues and hence different local interactions established among neighboring residues. Thus, it is possible that the Gly 8 in the ''foldable'' hybrids induces a thermodynamically favorable turn in loop 2. In addition, introducing a hydroxyl-bearing Thr may facilitate the formation of hydrogen bonds across the b-hairpin, similar to those observed in kalata B1 (40) , which may promote correct folding. Further amino acid replacements, such as substitution of the Thr in loop 6 with a non-hydroxyl containing residue, may provide additional information regarding the role of this residue in folding. However, it appears that the combination of the Gly in loop 2 and the Thr in loop 6 stabilizing factors is the minimal requirement to rescue the otherwise unfavorable in vitro folding of bracelet cyclotides.
To examine the possibility that these residues alternatively play a role earlier in the folding pathway, perhaps through mutual synergistic interactions, it was necessary to probe the structure of the nonnative three- It is interesting to note that the residues that were determined to be important for in vitro folding are present in the sequence of the ''natural chimera,'' kalata B8 (16) . Specifically, a Gly residue at the third position in loop 2 and a Thr at the start of loop 6 are present. The fact that kalata B8 folds into a native conformation in vitro further confirms that these residues in loops 2 and 6 have a prominent role in folding.
As the primary amino acid sequence in a protein is thought to dictate its folding mechanism and final topology (3, 19) , the question arises as to whether the sequence hypervariability observed in the cyclotides is associated with a large number of folding mechanisms. Alternatively, does the partial sequence conservation observed within each cyclotide subfamily mean that the conserved residues dictate a common mechanism for the subfamily? Detailed oxidative folding pathways have now been determined for a representative member from each of the three cyclotide subfamilies (1, 6, 15) . Mö bius and trypsin-inhibitor cyclotides have different folding pathways, despite having a common two-disulfide intermediate containing native-like disulfide bonds (6, 15) . In Mö bius cyclotides, this intermediate, despite having two native disulfide bonds, is not the direct precursor of the native form and requires disulfide reshuffling to convert into the native form (15) . The inability to isolate the direct precursor of the native form in the refolding of kalata B1 indicates that it is likely to be a transient intermediate. The intermediate seen for the prototypical trypsin inhibitor cyclotide MCoTI-II directly converts to the native form and appears to be an on-pathway intermediate. As already noted, a recent study that examined the folding bracelet cyclotide, cycloviolacin O2, identified a three-disulfide intermediate with nonnative bonds as the major species present during folding (1). Other one-disulfide and three-disulfide intermediates were also present as minor products during folding, but no two-disulfide intermediates were seen. Cycloviolacin O2 was also shown not to fold correctly under conditions generally used for kalata B1. Under the folding conditions used in this study, we also observed a suite of misfolded isomers for cycloviolacin O1. Collectively, these results suggest that folding of bracelet cyclotides occurs via a pathway that is different from both Mö bius and trypsin inhibitor subfamilies, at least in vitro.
The folding situation in vivo is likely to be more complex still, likely involving folding auxiliaries. For example, a protein disulfide isomerase was recently isolated from the cyclotide-producing plant Oldenlandia affinis and shown to facilitate cyclotide folding (26) . As well as delineating which residues are important for facilitating folding, the findings from the current study also identified regions within the cyclotide scaffold that are not important for folding and are thus permissive to mutations. This knowledge will facilitate the use of a range of cyclotides, including bracelet cyclotides, as grafting scaffolds in protein-engineering applications.
In summary, the current study has enhanced the information known regarding the folding of cyclotides and has provided a mechanistic insight into cyclotide folding, identifying the specific structural elements that influence correct folding, and demonstrated that they are localized within two intercysteine loops. More generally, the study complements other recent studies on the folding of a wide range of disulfide-rich peptides and proteins (2) .
